Blog

A new interesting article has been published in J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7. doi: 10.1016/j.jmii.2020.03.005. [Epub ahead of print] and titled:

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.

Authors of this article are:

Wu D, Yang XO.

A summary of the article is shown below:

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.Copyright © 2020. Published by Elsevier B.V.

Check out the article’s website on Pubmed for more information:

[link-preview url=https://www.ncbi.nlm.nih.gov/pubmed/32205092 forceshot=true]

This article is a good source of information and a good way to become familiar with topics such as: COVID-19; Cytokine storm; JAK2 inhibitor; SARS-CoV-2; TH17.

---

New Research Kits from MOLECULAR DEPOT

---

New Antibodies from MOLECULAR DEPOT

---

New Proteins from MOLECULAR DEPOT

---

New Chemicals from MOLECULAR DEPOT